Indianapolis-based Roche Diagnostics has received a key clearance from the U.S. Food and Drug Administration. Roche says it will be the first company of its kind in the U.S. to provide this type of technology for patients that may be experiencing a heart attack. The Elecsys Troponin T Gen 5 STAT test measures a specific marker in the blood stream that is released when heart cells are being damaged.
The company says 8 million emergency room visits per year are attributed to potential heart attack symptoms, but only 5-20 percent of them have actually suffered one. Roche Diagnostics says the test has been available throughout the rest of the world for the last seven years.
You can connect to more about the Troponin T Gen 5 STAT blood test approval by clicking here.